Cargando…
Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial
INTRODUCTION: Few treatment options exist for patients with systemic lupus erythematosus (SLE) who fail conventional therapy. Although widely used to treat lupus, the efficacy of B cell depletion therapy using rituximab has not been demonstrated in randomised clinical trials. Following rituximab, el...
Autores principales: | Jones, Alexis, Muller, Patrick, Dore, Caroline J, Ikeji, Felicia, Caverly, Emilia, Chowdhury, Kashfia, Isenberg, David A, Gordon, Caroline, Ehrenstein, Michael R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937022/ https://www.ncbi.nlm.nih.gov/pubmed/31848169 http://dx.doi.org/10.1136/bmjopen-2019-032569 |
Ejemplares similares
-
Safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial: statistical analysis plan
por: Muller, Patrick, et al.
Publicado: (2020) -
Belimumab in systemic lupus erythematosus
por: Vilas-Boas, Andreia, et al.
Publicado: (2015) -
Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison
por: Brunner, Hermine I, et al.
Publicado: (2021) -
Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol
por: Teng, Y K Onno, et al.
Publicado: (2019) -
Intravenous Immunoglobulin in the Management of Lupus Erythematosus Panniculitis
por: AlQadri, Nada G, et al.
Publicado: (2020)